Evidence map›Paper›PMID 22956822›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2012

Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease.

Marina O Ziehn, Andrea A Avedisian, Shannon M Dervin, Elizabeth A Umeda, Thomas J O'Dell, Rhonda R Voskuhl

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00405353 phase1 / phase2completednot on this map

Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial

TypeinterventionalSponsorUniversity of California, Los AngelesRan2002 to 2007Enrolled10ConditionsMultiple SclerosisArmsAndrogel 10 grams of gel containing 100 mg of testosterone
NCT03000127 phase2withdrawnnot on this mapstarted 2018, after this paper: background citation

A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis

TypeinterventionalSponsorUniversity of California, Los AngelesRan2018 to 2024Enrolled0ConditionsMultiple SclerosisArmsAndroGel 1 % Topical Gel, Placebos
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Roles of AMPA receptors in social behaviors.Frontiers in synaptic neuroscience · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. The X factor in neurodegeneration.The Journal of experimental medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marina O ZiehnInterdepartmental Program of Neuroscience, University of California, Los Angeles, California 90095, USA.
Andrea A Avedisian
Shannon M Dervin
Elizabeth A Umeda
Thomas J O'Dell
Rhonda R Voskuhl
University of California, Los Angeles · US

Funding

Neuroendocrinology, Sex Differences, and ReproductionT32HD007228 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARNOLD, ARTHUR P · 1985 to 2015
$3.9M
Treatment of Multiple Sclerosis with Sex HormonesK24NS062117 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2008 to 2012
$722k
Sex differences in the CNS during diseaseR21NS071210 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2010 to 2011
$420k
NICHD NIH HHS T32 HD007228NICHD NIH HHS T32 HD07228-26NIMH NIH HHS MH609197NINDS NIH HHS K24NS052117NINDS NIH HHS K24 NS062117NINDS NIH HHS R21 NS071210
6 · The paper itself

Abstract

Over 50% of multiple sclerosis (MS) patients experience cognitive deficits, and hippocampal-dependent memory impairment has been reported in >30% of these patients. While postmortem pathology studies and in vivo magnetic resonance imaging demonstrate that the hippocampus is targeted in MS, the neuropathology underlying hippocampal dysfunction remains unknown. Furthermore, there are no treatments available to date to effectively prevent neurodegeneration and associated cognitive dysfunction in MS. We have recently demonstrated that the hippocampus is also targeted in experimental autoimmune encephalomyelitis (EAE), the most widely used animal model of MS. The objective of this study was to assess whether a candidate treatment (testosterone) could prevent hippocampal synaptic dysfunction and underlying pathology when administered in either a preventative or a therapeutic (postdisease induction) manner. Electrophysiological studies revealed impairments in basal excitatory synaptic transmission that involved both AMPA receptor-mediated changes in synaptic currents, and faster decay rates of NMDA receptor-mediated currents in mice with EAE. Neuropathology revealed atrophy of the pyramidal and dendritic layers of hippocampal CA1, decreased presynaptic (Synapsin-1) and postsynaptic (postsynaptic density 95; PSD-95) staining, diffuse demyelination, and microglial activation. Testosterone treatment administered either before or after disease induction restores excitatory synaptic transmission as well as presynaptic and postsynaptic protein levels within the hippocampus. Furthermore, cross-modality correlations demonstrate that fluctuations in EPSPs are significantly correlated to changes in postsynaptic protein levels and suggest that PSD-95 is a neuropathological substrate to impaired synaptic transmission in the hippocampus during EAE. This is the first report demonstrating that testosterone is a viable therapeutic treatment option that can restore both hippocampal function and disease-associated pathology that occur during autoimmune disease.

Indexed as

AnimalsDisks Large Homolog 4 ProteinDrug ImplantsExcitatory Postsynaptic PotentialsGuanylate KinasesHippocampusMaleMembrane ProteinsMiceMice, Inbred C57BLPolyradiculoneuropathyRandom AllocationSynaptic TransmissionTestosteroneDisks Large Homolog 4 ProteinDlg4 protein, mouseDrug ImplantsGuanylate KinasesMembrane ProteinsTestosterone

Identifiers

PMID22956822
PMCPMC3571760
OpenAlexW2107066201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.